Drug Interactions between Daxxify and fesoterodine
This report displays the potential drug interactions for the following 2 drugs:
- Daxxify (daxibotulinumtoxinA)
- fesoterodine
Interactions between your drugs
fesoterodine daxibotulinumtoxinA
Applies to: fesoterodine and Daxxify (daxibotulinumtoxinA)
MONITOR: Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders. Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.
MANAGEMENT: Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.
References (8)
- "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals
- "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc
- "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc
- (2022) "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals
- (2022) "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.
- (2022) "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc., 1
- (2022) "Product Information. Letybo (letibotulinumtoxinA)." CROMA Australia Pty Ltd, 1
- (2024) "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics
Drug and food interactions
fesoterodine food
Applies to: fesoterodine
MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.
MANAGEMENT: Caution is advised if fesoterodine is administered with grapefruit or grapefruit juice. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.
References (1)
- (2008) "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.